HONG KONG – Taiwan-based biopharma JHL Biotech Inc. secured its first clinical trial approval from the China National Drug Administration (CNDA) for its biosimilar pipeline, aiming to kick off a phase I trial over the next few months to test JHL-1101, a biosimilar rituximab for treating non-Hodgkin's lymphoma (NHL).

HONG KONG – Taiwan-based biopharma JHL Biotech Inc. secured its first clinical trial approval from the China National Drug Administration (CNDA) for its biosimilar pipeline, aiming to kick off a phase I trial over the next few months to test JHL-1101, a biosimilar rituximab for treating non-Hodgkin's lymphoma (NHL).